shot-button
Maharashtra Elections 2024 Maharashtra Elections 2024
Home > News > India News > Article > Marion Biotechs production licence suspended

Marion Biotech’s production licence suspended

Updated on: 13 January,2023 08:50 AM IST  |  Noida
Agencies |

The World Health Organisation (WHO) has also issued a medical product alert on Ambronol and Dok-1 Max syrups, both manufactured by Marion Biotech in Noida, Uttar Pradesh

Marion Biotech’s production licence suspended

The office of Emenox Group’s Marion Biotech pharmaceutical firm in Noida. Pic/PTI

The production licence of Noida-based pharmaceutical firm Marion Biotech, allegedly linked to the deaths of 18 children in Uzbekistan, has been suspended while the results of its controversial cough syrup are awaited, an Uttar Pradesh drug official said on Thursday.


The World Health Organisation (WHO) has also issued a medical product alert on Ambronol and Dok-1 Max syrups, both manufactured by Marion Biotech in Noida, Uttar Pradesh. A team of central agencies and the Uttar Pradesh drug department had carried out an inspection at the firm’s office here on December 29 and taken six more samples for testing.


During the inspection, the company representatives could not produce documents related to the production of ‘Dok-1 max’ cough syrup, prompting the government to order halting of its production immediately, Gautam Buddh Nagar Drug Inspector Vaibhav Babbar said. “The production licence of the firm remains suspended, as was ordered on December 29. Now the suspension order has been issued in writing to the firm on January 10 and has been acknowledged by the firm,” Babbar said.


Also Read: 'Substandard': WHO warns against use of Indian cough syrups linked to Uzbekistan deaths

On the status of the test results, the officer said the samples were taken by the central agencies and their results are yet to arrive. Marion Biotech did not sell ‘Dok-1 Max’ and Ambronol in India and its only export has been to Uzbekistan, Babbar said on Thursday and estimated that the company exported around 1 lakh Dok-1 Max syrups in 45 days. On Wednesday, the WHO also issued a ‘medical product alert’, referring to two substandard (contaminated) products, identified in Uzbekistan and reported to it on December 22, 2022.

According to WHO, substandard medical products are those that fail to meet quality standards or specifications and are therefore “out of specification.”“The two products are AMBRONOL syrup and DOK-1 Max syrup. The stated manufacturer of both products is MARION BIOTECH PVT. LTD, (Uttar Pradesh, India). To date, the stated manufacturer has not provided guarantees to WHO on the safety and quality of these products,” the WHO stated. “Laboratory analysis of samples of both products, undertaken by national quality control laboratories of the Ministry of Health of the Republic of Uzbekistan found both products contained unacceptable amounts of diethylene glycol and/or ethylene glycol as contaminants,” it said.  The global health body said that diethylene glycol and ethylene glycol are toxic to humans when consumed and can prove fatal.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK